Plasma GFAP concentration has been correlated with cortical amyloid status derived from 18F-flutemetamol amyloid PET scans [15, 16], and the longitudinal change in GFAP was associated to the development of clinical AD and cognitive decline [17]. Here, GFAP is linked to Alzheimer disease.